₹40.75
▲ +1.7 +4.35%
17 Jul 2026
BSE Listed
Goldline Pharmaceutical Limited (544759)
Volume: 54,000Avg Vol 1W: 29,400Avg Vol 1M: 86,59152W Range:₹38.25₹60
Key Ratios
Checked 2h agoMarket Cap₹39 Cr
Current Price₹40.75
Previous Close₹39.05
High / Low (52w)₹60 / ₹38.25
Volume54,000
Avg Vol (1W)29,400
Avg Vol (1M)86,591
Stock P/E—
Book Value₹21
Dividend Yield0%
ROE28.89%
ROA9.56%
Revenue (TTM)—
Revenue Growth—
Profit Margin0%
Total Debt—
Shares Outstanding1 Cr
Face Value—
EPS (TTM)₹0
P/B1.94
Debt / Equity1.22
50 DMA—
200 DMA—
Day change+4.35%
Price Chart
₹40.75▼ 28.22% · 1Y
2026-05-192026-07-17
20-day avg volume: 69K shares
Pros
- Healthy return on equity of 28.9%.
- Company is almost debt-free.
- Revenue grew 19% YoY.
- Net profit is growing year over year.
Profit & Loss (Annual)
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Revenue | ₹20 Cr | ₹24 Cr | ₹28 Cr |
| EBITDA | ₹2 Cr | ₹4 Cr | ₹6 Cr |
| Net Profit | ₹0 Cr | ₹2 Cr | ₹3 Cr |
| EPS | 0.43 | 3.01 | 4.11 |
Balance Sheet
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Total Assets | ₹19 Cr | ₹23 Cr | ₹26 Cr |
| Total Liabilities | ₹14 Cr | ₹15 Cr | ₹16 Cr |
| Equity | ₹6 Cr | ₹8 Cr | ₹10 Cr |
| Total Debt | — | — | — |
Cash Flow
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Operating | ₹2 Cr | ₹3 Cr | ₹3 Cr |
| Investing | ₹-1 Cr | ₹-1 Cr | ₹0 Cr |
| Financing | ₹-1 Cr | ₹-1 Cr | ₹-2 Cr |
| Free Cash Flow | ₹2 Cr | ₹3 Cr | ₹3 Cr |
Shareholding
Promoter 57.29% Institutions 12.97% Public 29.74%
Efficiency & Working Capital
ROCE28.4%
Interest Coverage3
Dividend Payout—
Debtor Days139 d
Inventory Days88 d
Payable Days27 d
Cash Conversion Cycle201 d
Working Capital Days227 d
Shareholding Details
As of 2026-05-31
Promoter57.3%
FII5.2%
DII7.8%
Institutions13%
Public29.7%
Promoter Pledge0%
No. of Shareholders271
Shareholding Pattern
Quarterly — figures in %. Latest 2 quarters.
| Period | Sept 2025 | May 2026 |
|---|---|---|
| Promoters | 79.7% | 57.3% |
| FIIs | 0% | 5.2% |
| DIIs | 0% | 7.8% |
| Public | 20.3% | 29.7% |
| Promoter Pledge | 0% | 0% |
| No. of Shareholders | 20 | 271 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Swapan Khandelwal | Shareholding of Promoter and Promoter Group | 28.7% | 27,49,988 |
| Amol Laxmikant Mujumdar | Shareholding of Promoter and Promoter Group | 28.7% | 27,49,988 |
| Sumit Bilgaiyan | Public Shareholding | 7% | 6,75,000 |
| Upsurge Opportunities Fund 1 | Public Shareholding | 3.9% | 3,75,000 |
| Vikasa India Eif I Fund- Share Class P | Public Shareholding | 3.8% | 3,66,000 |
| Priya Chandrakant Jalgaonkar | Public Shareholding | 2.3% | 2,25,000 |
| Sgmp Management Consultancy Private Limited | Public Shareholding | 2% | 1,90,000 |
| M/s Nirman Share Brokers Pvt. Ltd. - Pro Account-prop | Public Shareholding | 1.4% | 1,38,000 |
| Meena Nayan Patel | Public Shareholding | 1% | 1,00,000 |
| Asha Khandelwal | Shareholding of Promoter and Promoter Group | 0% | 3 |
| Aishwarya Amol Mujumdar | Shareholding of Promoter and Promoter Group | 0% | 3 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Swapan Khandelwal | 0 | 0% | 2026-05-17 |
| Amol Laxmikant Mujumdar | 0 | 0% | 2026-05-17 |
| Asha Khandelwal | 0 | 0% | 2026-05-17 |
| Aishwarya Amol Mujumdar | 0 | 0% | 2026-05-17 |
| Upsurge Opportunities Fund 1 | 0 | 0% | 2026-05-17 |
| Vikasa India Eif I Fund- Share Class P | 0 | 0% | 2026-05-17 |
| Meena Nayan Patel | 0 | 0% | 2026-05-17 |
| Priya Chandrakant Jalgaonkar | 0 | 0% | 2026-05-17 |
| Sumit Bilgaiyan | 0 | 0% | 2026-05-17 |
| Sgmp Management Consultancy Private Limited | 0 | 0% | 2026-05-17 |
| M/s Nirman Share Brokers Pvt. Ltd. - Pro Account-prop | 0 | 0% | 2026-05-17 |
| Amol Laxmikant Mujumdar | 0 | 0% | 2025-09-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| AMOL LAXMIKANT MUJUMDAR | Chairman / Executive Director / M D / Promoter | 2025 |
| Swapan Prernprakash Khandelwal | WTD & Executive Director | 2025 |
| Prashant Shriknshna Karkare | Executive Director | 2025 |
| Avinash Pandurang Ambulkar | Executive Director | 2025 |
| Prashant Vithal Rahate | Non Executive Director | 2025 |
| Mehul Hari Ranade | Independent Non Exe. Director | 2025 |
| Renuka Saurabh Borole | Independent Non Exe. Director | 2025 |
| Shraddha Kiran Kulkarni | Independent Non Exe. Director | 2025 |
| Ruchi Sanket Modi | Company Sec. & Compli. Officer | 2025 |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 11 | 7 | 7 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 1 | 12 | 14 |
| 2025 | 0 | 0 | 0 | 1 | 4 | 5 |
| 2025 | 0 | 0 | 0 | 0 | 8 | 8 |
Company Information
🌐 www.goldlinepharma.in ↗
📍 103 F-1 Leela Apartment Shilpa, HSG Society Shanidham Narendra, Nagpur, Maharashtra, 440015
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
IPO History
| IPO | listed · listed 2026-05-19 |
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search